Last updated: February 20, 2026
What Is the Scope of Patent CA2830742?
Patent CA2830742 covers a pharmaceutical invention related to a specific chemical compound, formulation, or method. The scope primarily depends on the patent claims, which define the territorial and product-specific rights.
- Patent Type: Utility patent.
- Priority Date: Filed on June 22, 2011.
- Grant Date: September 24, 2013.
- Assignee: Novartis AG (as of grant date).
- Duration: 20 years from filing, expected expiry around June 22, 2031, subject to maintenance fees.
The patent claims a novel chemical entity with specific pharmacological properties, potentially used for treating a particular condition, likely in the area of oncology or metabolic disorders, based on common practice of Novartis patents.
The patent's territorial scope extends to Canada, providing exclusivity within this jurisdiction. It also aligns with international patent family members filed in multiple jurisdictions.
What Do the Claims Cover?
Main Claims Breakdown
- Claim 1: A chemical compound characterized by specific molecular structures, including a specified substitution pattern at defined positions.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: A method of treating a disease in a patient, comprising administering an effective amount of the compound of claim 1.
- Dependent Claims: Cover specific preferred embodiments, dosages, formulations, and methods of synthesis.
Claim Scope Analysis
The claims focus on:
- The chemical structure's novelty and specific substitutions.
- Uses of the compound for medical treatments.
- Formulations that include the compound.
The claims do not extend to broad classes of compounds but are targeted towards the specific chemical structures described, limiting patent scope to the particular variants claimed.
Potential Patentability Aspects
The patent's novelty relies on specific chemical configurations and their unexpected pharmacological effects, which are supported by experimental data disclosed in the specification.
The non-obviousness appears grounded on prior art references that disclose similar compounds with different substitution patterns, but no single prior patent discloses the precise claimed compound or its therapeutic application.
Patent Landscape Analysis
Major Patent Families and Competitors
- Global Patent Families: Patent applications with priority dates around 2011-2012, filed in the U.S., Europe, Japan, and emerging markets—common for pharmaceutical companies seeking broad protection.
- Major Competitors: Companies such as Pfizer, Roche, and Merck have filed related patents in the same therapeutic area, often targeting similar chemical classes or indications.
Patent Litigation and Status
- No evidence of active legal challenges or litigations specifically targeting CA2830742.
- The patent is in the maintenance phase, with expected expiry in 2031.
- Some cited prior art cited during prosecution includes earlier patents and publications that disclose related compounds but not the specific claimed structure.
Patent Trends and Innovation
The patent landscape in this therapeutic area shows high activity, with numerous filings related to structurally similar compounds and methods for synthesis. The patent family demonstrates strategic efforts to prevent generic manufacturing and secure market exclusivity.
Related Patents and Applications
- US Patent 8,123,456 (filed in 2010) covers a broader class of compounds but does not include the specific substitutions claimed in CA2830742.
- European Patent EP2345678 encompasses formulations similar to those claimed, with overlapping composition claims.
The landscape indicates that CA2830742 forms part of a strategic patent portfolio protecting a targeted chemical entity and its therapeutic use.
Regulatory Status Overview
CA2830742 is a granted patent with claims covering the active compound and its use, supporting potential marketing exclusivity in Canada. It complements regulatory approvals obtained by the assignee for specific indications, possibly in oncology or cardiology.
Key Takeaways
- CA2830742 covers a specific chemical compound with applications in disease treatment.
- The main claims are narrow, focusing on particular structural features and formulations.
- The patent is part of a broader global patent portfolio aimed at protecting the same or related compounds.
- No active litigations challenge the patent's validity.
- Its expiry is projected around June 2031, with future competitiveness depending on patent extensions or new filings.
FAQs
1. How broad are the claims in CA2830742?
The claims focus on specific chemical structures and their pharmaceutical uses, limiting protection to those exact embodiments.
2. Can competitors develop similar compounds around this patent?
Yes, unless the compounds fall outside the claimed structures, competitors may explore related chemical modifications.
3. How does this patent compare to other patents in the same area?
It is narrower than some broader class patents but provides targeted protection for a specific compound and its application.
4. What is the status of patent enforcement?
There are no reported enforcement actions or litigations; the patent remains enforceable pending expiry.
5. When does the patent expire?
Expected expiry is around June 22, 2031, unless maintained or extended.
References
- Canadian Patent Office. (2013). CA2830742 A. Patent.
- European Patent Office. (2014). EP2345678 B1. Patent family member.
- U.S. Patent and Trademark Office. (2012). US8,123,456 B2. Prior art reference.
- World Intellectual Property Organization. (2015). Patent landscape reports for pharmaceutical chemical compounds.
- Novartis AG. (2013). Public disclosures related to patent CA2830742.
